Long-Term Follow-Up of Chemotherapy-Induced Ovarian Failure in Young Breast Cancer Patients: The Role of Vascular Toxicity

被引:32
作者
Ben-Aharon, Irit [1 ,4 ]
Granot, Tal [1 ]
Meizner, Israel [2 ,4 ]
Hasky, Noa [4 ]
Tobar, Ana [3 ]
Rizel, Shulamith [1 ,4 ]
Yerushalmi, Rinat [1 ,4 ]
Ben-Haroush, Avi [2 ,4 ]
Fisch, Benjamin [2 ,4 ]
Stemmer, Salomon M. [1 ,4 ]
机构
[1] Helen Schneider Hosp Women, Davidoff Ctr, Inst Oncol, Petah Tiqwa, Israel
[2] Helen Schneider Hosp Women, Dept Obstet & Gynecol, Petah Tiqwa, Israel
[3] Rabin Med Ctr, Dept Pathol, Petah Tiqwa, Israel
[4] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
基金
以色列科学基金会;
关键词
Chemotherapy; Ovarian toxicity; Vascular toxicity; Anti-Mullerian hormone; ANTI-MULLERIAN HORMONE; PREMENOPAUSAL WOMEN; ADJUVANT CHEMOTHERAPY; AMENORRHEA; AGE; MENOPAUSE; RESERVE; DAMAGE; TIME;
D O I
10.1634/theoncologist.2015-0044
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. We previously reported that chemotherapy-induced ovarian toxicity may result from acute vascular insult, demonstrated by decreased ovarian blood flow and diminished post-treatment anti-Mullerian hormone (AMH) levels. In the present study, we report the continuous prospective evaluation of ovarian function in that cohort. Methods. Patients (aged <43years) with localized breast cancer were evaluated by transvaginal ultrasound prior to initiation of chemotherapy, immediately at treatment completion, and at 6 and 12 months after treatment cessation. Doppler flow velocity indices of the ovarian vasculature (resistance index [RI], pulsatility index [PI]) were visualized. Hormone markers of ovarian reserve were assessed at the same time points. Results. Twenty patients were enrolled in the study. Median age was 34 +/- 5.24 years. Ovarian blood flow was significantly reduced immediately following chemotherapy (both RI and PI; p = .01). These parameters were partially recovered at later points of assessment (6 and 12 months after treatment); patients aged <35 years significantly regained ovarian blood flow compared with patients aged >35 years (p < .05). AMH dropped dramatically in all patients following treatment (p < .001) and recovered in only 10 patients. Hormone markers of ovarian reserve shortly after chemotherapy depicted a postmenopausal profile for most patients, accompanied by related symptoms. Follicle-stimulating hormone (FSH) levels recovered in 14 of 20 patients and significantly returned to the premenopausal range in patients aged <35 years (p = .04); 10 of 20 resumed menses at 12 months. The pattern of vascular impairment was lessened in patients treated with a trastuzumab-based protocol, although results did not reach statistical significance (p=.068). Conclusion. Continuous prospective evaluation of ovarian vasculature and function in a cohort of young patients during and after chemotherapy indicated that ovarian toxicity may derive from acute vascular insult. Age may affect whether patients regain ovarian function, whereas recovery of blood flow and premenopausal FSH levels at later assessment was notable in patients aged <35 years.
引用
收藏
页码:985 / 991
页数:7
相关论文
共 26 条
[1]   The Effects of Paclitaxel, Dose Density, and Trastuzumab on Treatment-Related Amenorrhea in Premenopausal Women With Breast Cancer [J].
Abusief, Mary E. ;
Missmer, Stacey A. ;
Ginsburg, Elizabeth S. ;
Weeks, Jane C. ;
Partridge, Ann H. .
CANCER, 2010, 116 (04) :791-798
[2]   In vivo Bioimaging as a Novel Strategy to Detect Doxorubicin-Induced Damage to Gonadal Blood Vessels [J].
Bar-Joseph, Hadas ;
Ben-Aharon, Irit ;
Tzabari, Moran ;
Tsarfaty, Galia ;
Stemmer, Salomon M. ;
Shalgi, Ruth .
PLOS ONE, 2011, 6 (09)
[3]   Doxorubicin-Induced Vascular Toxicity - Targeting Potential Pathways May Reduce Procoagulant Activity [J].
Ben Aharon, Irit ;
Bar Joseph, Hadas ;
Tzabari, Moran ;
Shenkman, Boris ;
Farzam, Nahid ;
Levi, Mattan ;
Shalgi, Ruth ;
Stemmer, Salomon M. ;
Savion, Naphtali .
PLOS ONE, 2013, 8 (09)
[4]   Chemotherapy-Induced Ovarian Failure as a Prototype for Acute Vascular Toxicity [J].
Ben-Aharon, Irit ;
Meizner, Israel ;
Granot, Tal ;
Uri, Shiri ;
Hasky, Noa ;
Rizel, Shulamith ;
Yerushalmi, Rinat ;
Sulkes, Aaron ;
Stemmer, Salomon M. .
ONCOLOGIST, 2012, 17 (11) :1386-1393
[5]   Doxorubicin-induced ovarian toxicity [J].
Ben-Aharon, Irit ;
Bar-Joseph, Hadas ;
Tzarfaty, Galia ;
Kuchinsky, Lital ;
Rizel, Shulamith ;
Stemmer, Salomon M. ;
Shalgi, Ruth .
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2010, 8
[6]   Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer [J].
Bines, J ;
Oleske, DM ;
Cobleigh, MA .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) :1718-1729
[7]   Anti-Mullerian Hormone Predicts Menopause: A Long-Term Follow-Up Study in Normoovulatory Women [J].
Broer, S. L. ;
Eijkemans, M. J. C. ;
Scheffer, G. J. ;
van Rooij, I. A. J. ;
de Vet, A. ;
Themmen, A. P. N. ;
Laven, J. S. E. ;
de Jong, F. H. ;
Velde, E. R. Te ;
Fauser, B. C. ;
Broekmans, F. J. M. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (08) :2532-2539
[8]  
CLARK JG, 1900, J HOPKINS HOSP REP, V9, P593
[9]   Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3 [J].
Fanchin, R ;
Schonäuer, LM ;
Righini, C ;
Guibourdenche, J ;
Frydman, R ;
Taieb, J .
HUMAN REPRODUCTION, 2003, 18 (02) :323-327
[10]   Anti-Mullerian Hormone as a Predictor of Time to Menopause in Late Reproductive Age Women [J].
Freeman, Ellen W. ;
Sammel, Mary D. ;
Lin, Hui ;
Gracia, Clarisa R. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (05) :1673-1680